PYC Therapeutics Ltd (ASX: PYC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
PYC Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.26 billion
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
983.26 million
Earnings per share
-0.083
Dividend per share
N/A
Year To Date Return
-23.90%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
PYC Therapeutics Ltd (ASX: PYC)
Latest News
Broker Notes
Experts reveal 4 ASX small-cap shares to buy now
Share Fallers
Why Australian Ethical, PYC, Resolute, and Star shares are falling today
Healthcare Shares
2 ASX healthcare small-cap shares to buy now: brokers
Broker Notes
8 ASX All Ords shares upgraded to 'strong buy' ratings in November
Share Gainers
3 ASX All Ords shares rocketing over 12% on Thursday
Share Fallers
Why Actinogen, Aurizon, Beach Energy, and PYC shares are sinking today
Share Gainers
Why these three ASX All Ords stocks are leading the charge higher this week
Share Gainers
Why IDP Education, Novonix, PYC, and Regis Resources share are racing higher
Small Cap Shares
2 ASX penny stocks to consider buying while their prices are this cheap
Share Gainers
Why Appen, Mayne Pharma, Playside, and PYC shares are storming higher
Healthcare Shares
Guess which ASX All Ords insider just bought 50 million shares in their company
Share Fallers
Why IDP Education, JB Hi-Fi, PYC, and Renascor shares are falling today
PYC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About PYC Therapeutics Ltd
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001 and is headquartered in Nedlands, Australia.
PYC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 17 Apr 2026 | $1.28 | $0.05 | 4.07% | 1,406,322 | $1.23 | $1.31 | $1.22 |
| 16 Apr 2026 | $1.23 | $0.02 | 1.65% | 864,928 | $1.23 | $1.25 | $1.20 |
| 15 Apr 2026 | $1.21 | $0.06 | 5.22% | 1,287,849 | $1.15 | $1.27 | $1.15 |
| 14 Apr 2026 | $1.15 | $0.00 | 0.00% | 944,225 | $1.15 | $1.19 | $1.15 |
| 13 Apr 2026 | $1.15 | $-0.03 | -2.55% | 956,818 | $1.17 | $1.17 | $1.13 |
| 10 Apr 2026 | $1.18 | $0.06 | 5.38% | 822,959 | $1.20 | $1.20 | $1.13 |
| 09 Apr 2026 | $1.12 | $-0.04 | -3.45% | 736,869 | $1.20 | $1.20 | $1.10 |
| 08 Apr 2026 | $1.16 | $0.09 | 8.45% | 822,836 | $1.10 | $1.18 | $1.10 |
| 07 Apr 2026 | $1.07 | $-0.05 | -4.48% | 576,349 | $1.11 | $1.12 | $1.05 |
| 02 Apr 2026 | $1.12 | $-0.05 | -4.29% | 1,065,174 | $1.18 | $1.18 | $1.09 |
| 01 Apr 2026 | $1.17 | $0.06 | 5.45% | 2,483,883 | $1.16 | $1.21 | $1.13 |
| 31 Mar 2026 | $1.10 | $-0.01 | -0.90% | 906,838 | $1.15 | $1.16 | $1.07 |
| 30 Mar 2026 | $1.12 | $0.01 | 0.91% | 1,050,058 | $1.12 | $1.14 | $1.08 |
| 27 Mar 2026 | $1.10 | $-0.07 | -5.98% | 2,367,850 | $1.19 | $1.19 | $1.09 |
| 26 Mar 2026 | $1.17 | $-0.05 | -4.10% | 961,087 | $1.25 | $1.25 | $1.15 |
| 25 Mar 2026 | $1.22 | $0.04 | 3.39% | 2,358,979 | $1.13 | $1.24 | $1.13 |
| 24 Mar 2026 | $1.18 | $-0.02 | -1.67% | 1,437,416 | $1.23 | $1.26 | $1.16 |
| 23 Mar 2026 | $1.20 | $-0.13 | -9.77% | 1,963,382 | $1.31 | $1.31 | $1.19 |
| 20 Mar 2026 | $1.33 | $-0.03 | -2.20% | 661,267 | $1.37 | $1.38 | $1.33 |
| 19 Mar 2026 | $1.37 | $-0.03 | -2.15% | 2,105,928 | $1.42 | $1.42 | $1.34 |
| 18 Mar 2026 | $1.40 | $0.03 | 2.20% | 3,173,656 | $1.38 | $1.43 | $1.37 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Mar 2026 | Rohan Hockings | Buy | 82,550 | $99,883 |
On-market trade.
|
| 06 Mar 2026 | Rohan Hockings | Issued | 80,010 | $120,015 |
Rights issue.
|
| 06 Mar 2026 | Ian Constable | Issued | 123,000 | $184,500 |
Rights issue.
|
| 23 Dec 2025 | Peter Coleman | Issued | 2,000,000 | $3,120,000 |
Director remuneration.
|
| 26 Nov 2025 | Rohan Hockings | Buy | 133,350 | $200,003 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Professor Ian Jeffrey Constable | Non-Executive Director | Sep 2025 |
Professor Constable was the Foundation Lions Professor of Ophthalmology at the University of Western Australia, Foundation Chair of the Australian Association of Ophthalmology and Visual Science, and Founding Managing Director of the Lions Eye Institute Limited. Professor Constable is a member of the Advisory Board of the Lowy Medical Research Institute based in San Diego and Chair of the Scientific Advisory board of the Snow Vision Accelerator. US based Directors.
|
| Mr Peter John Coleman | Non-Executive ChairmanNon-Executive Director | Nov 2025 |
Mr Coleman previously served as the CEO of Woodside between 2011 and 2021 and brings experience across both commercial and corporate governance domains with particular expertise in corporate and asset-level mergers and acquisitions.
|
| Dr Rohan Hockings | Chief Executive OfficerManaging Director | Aug 2016 |
Dr Hockings spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. He is a founding principal of a private equity fund active in the acquisition of health care assets within Australia. His previous roles include strategy and operational advisory positions with a global management consulting firm, equity capital markets experience as a solicitor with a national law firm and several appointments as a medical practitioner.
|
| Mr Daniel Coletta | Joint Company Secretary | Mar 2026 |
-
|
| Daniel Coletta | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Australian Land Pty Ltd <The Southdown A/C> | 76,568,655 | 13.13% |
| Hsbc Custody Nominees (Australia) Limited | 48,518,521 | 8.32% |
| Citicorp Nominess Pty Limited | 34,134,159 | 5.85% |
| Mccusker Holdings Pty Ltd | 23,258,000 | 3.99% |
| Pagham Pty Ltd <The Aintree A/C> | 22,574,796 | 3.87% |
| Runcton Pty Ltd <The Goodwood A/C> | 22,574,796 | 3.87% |
| Stockbridge Corporation Pty Ltd <The Ascot A/C> | 22,574,796 | 3.87% |
| Trexon Pty Ltd Blackpool Trust A/C> | 22,574,796 | 3.87% |
| J P Morgan Nominees Australia Pty Limited | 19,179,605 | 3.29% |
| Sietsma Holdings Pty Ltd <The Sietsma Super Fund A/C> | 16,875,000 | 2.89% |
| National Nominees Limited | 15,025,437 | 2.58% |
| Australian Land Pty Ltd <The Tribe Super Fund A/C> | 11,313,636 | 1.94% |
| Datamatch Pty Ltd <Paragon Family A/C> | 9,000,000 | 1.54% |
| Mr Adrian Bonaddio | 8,249,561 | 1.41% |
| Mr John Baird | 6,400,266 | 1.10% |
| Masali Pty Ltd | 5,334,329 | 0.91% |
| Locca Pty Ltd | 5,209,172 | 0.89% |
| Mr Adam Bonaddio | 5,002,069 | 0.86% |
| Selwood Barton Pty Ltd <Selwood Barton A/C> | 4,820,000 | 0.83% |
| Mccusker Foundation Ltd <The Mccusker Charitable A/C> | 4,200,000 | 0.72% |
